Positionspapier zum Post-COVID-Syndrom

Deleted Journal, Год журнала: 2025, Номер unknown

Опубликована: Фев. 3, 2025

---

Host-targeted antivirals against SARS-CoV-2 in clinical development - prospect or disappointment?

Antiviral Research, Год журнала: 2025, Номер 235, С. 106101 - 106101

Опубликована: Фев. 7, 2025

The global response to the COVID-19 pandemic, caused by novel SARS-CoV-2 virus, has seen an unprecedented increase in development of antiviral therapies. Traditional strategies have primarily focused on direct-acting antivirals (DAAs), which specifically target viral components. In recent years, increasing attention was given alternative approach aiming exploit host cellular pathways or immune responses inhibit replication, led so-called host-targeted (HTAs). emergence and promoted a boost this field. Numerous HTAs been tested demonstrated their potential against through vitro vivo studies. However, striking contrast, only limited number successfully progressed advanced clinical trial phases (2-4), even less entered practice. This review aims explore current landscape targeting that reached phase 2-4 trials. Additionally, it will challenges faced gaining regulatory approval market availability.

Язык: Английский

---

Bio-waste derived Ag/chitin nanocatalyst induces green and efficient N-alkylation of alcohols with amines via borrowing hydrogen strategy

Chemical Engineering Journal, Год журнала: 2025, Номер unknown, С. 160587 - 160587

Опубликована: Фев. 1, 2025

Язык: Английский

---

Sigma-1 receptors and geriatric pharmacology

Geriatric Pharmacology, Год журнала: 2025, Номер 1(sup1)

Опубликована: Янв. 18, 2025

Язык: Английский

---

A systematic review and meta-analysis, investigating dose and time of fluvoxamine treatment efficacy for COVID-19 clinical deterioration, death, and Long-COVID complications

Scientific Reports, Год журнала: 2024, Номер 14(1)

Опубликована: Июнь 12, 2024

Abstract There have been 774,075,242 cases of COVID-19 and 7,012,986 deaths worldwide as January 2024. In the early stages pandemic, there was an urgent need to reduce severity disease prevent for hospitalization avoid stress on healthcare systems worldwide. The repurposing drugs clinical deterioration patients trialed in many studies using different drugs. Fluvoxamine (an SSRI sigma-1 receptor agonist) initially identified potentially provide beneficial effects COVID-19-infected patients, preventing hospitalization. Fourteen carried out date, with seven those being randomized placebo-controlled studies. This systematic review meta-analysis covers literature from outbreak SARS-CoV-2 late 2019 until Search terms related fluvoxamine, such its trade names chemical names, along words COVID-19, coronavirus, were used databases including PubMed, Google Scholar, Scopus, ClinicalTrials.gov database NIH, identify trials subsequent analysis. Clinical death data extracted these where available meta-analysis. A total 7153 studied across 14 (both open-label double-blind placebo-controlled). 681 3553 (19.17%) standard care group 255 3600 (7.08%) fluvoxamine-treated experienced deterioration. estimated average log odds ratio 1.087 (95% CI 0.200 1.973), which differed significantly zero (z = 2.402, p 0.016). resulted a 0.359 0.1111 0.5294), 3.103, 0.002). results this study fluvoxamine effective deterioration, subgrouping analysis suggests that earlier treatment dose 200 mg or above provides best outcomes. We hope outcomes can help design future into respiratory viral infections improve

Язык: Английский

---

Real world effectiveness of early ensitrelvir treatment in patients with SARS-CoV-2, a retrospective case series

New Microbes and New Infections, Год журнала: 2024, Номер 62, С. 101522 - 101522

Опубликована: Окт. 30, 2024

Ensitrelvir, a 3C-like protease inhibitor, received emergency approval in Japan November 2022 for treating non-hospitalized patients with mild-to-moderate COVID-19. However, confirmation of its real-world clinical effectiveness is limited.

Язык: Английский

---

Die Bedeutung von Antidepressiva bei COVID-19 und Long-COVID – Ein Scoping-Review Update

Fortschritte der Neurologie · Psychiatrie, Год журнала: 2024, Номер unknown

Опубликована: Сен. 23, 2024

Introduction Preclinically, fluvoxamine and other antidepressants (AD) exerted antiviral anti-inflammatory properties also against SARS-COV-2. Therfore, It makes sense to test the clinical effect of AD COVID-19 Long COVID.

Язык: Английский

---

Potential consequences of ineffective COVID‐19 antiviral management

Academic Emergency Medicine, Год журнала: 2024, Номер 31(9), С. 947 - 948

Опубликована: Май 20, 2024

The author declares no conflict of interest.

Язык: Английский

---

News on the Role of Antidepressants in and for COVID-19 and Long COVID

Pharmacopsychiatry, Год журнала: 2024, Номер unknown

Опубликована: Сен. 26, 2024

Язык: Английский

---